BHST BioHarvest Sciences Inc. Common Stock
USBasic MaterialsAs of 2026-07-10 16:00
Why BHST matters now
BioHarvest Sciences Inc. Common Stock (BHST) is a US stock in Basic Materials. The latest InvestLog snapshot shows $2.78 with +0.72% on the session and $48.2M in market capitalization; recent performance reads 1-month -16.84% and YTD -37.19%.
The latest financial table shown here is Q1 2026, with revenue of $8.5M, net income of $-2.6M, and EPS of $-0.12. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -17.2%.
The latest indexable market news headline is "BioHarvest Sciences to Present at the 2026 BIO International Convention" from Newsfile Corp.
Additional event context on this page matters because analyst consensus is Buy with a median target of $10.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.21
P/S
1.61
EV/EBITDA
-8.04
DCF Value
$-259.14
FCF Yield
-17.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
59.5%
Operating Margin
-16.2%
Net Margin
-32.5%
ROE
-88.0%
ROA
-25.1%
ROIC
-14.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $8.5M | $-2.6M | $-0.12 |
| Q4 2025 | $9.1M | $-2.2M | $-0.12 |
| FY 2025 | $34.5M | $-11.1M | $-0.60 |
| Q3 2025 | $9.1M | $-2.5M | $-0.14 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$10.00
Target (Median)
$10.00
Target Range
$10.00 - $10.00
Related Stocks
Latest News
Company Info
Sector
Basic Materials
Industry
Agricultural Inputs
Country
CA
Exchange
—
Beta
1.37
BioHarvest Sciences Inc. functions as a biotechnology firm with operations segmented into Nutraceuticals and Pharmaceuticals. A key innovation is its proprietary botanical synthesis platform technology, which allows for the cultivation of active ingredients found within plant enzymes or cells. The company harnesses this advanced technology to craft evidence-based and clinically validated therapeutic products for both its nutraceutical and pharmaceutical offerings. Beyond its own development, it also provides contract development and manufacturing services. Its product portfolio includes various wellness items, notably VINIA, a dietary supplement derived from red grape cells, which delivers the full spectrum of polyphenols naturally present in red grapes. The company conducts business in Israel and the United States, with its corporate base in Vancouver, Canada.